Literature DB >> 7750940

Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients.

D Malide1, P Russo, M Bendayan.   

Abstract

Tumor necrosis factor alpha (TNF alpha) and interleukin-6 (IL-6) antigenic sites were shown within the resident glomerular mesangial cells of lupus nephritis patients applying the colloidal gold immunocytochemical approach at the electron microscopic level. Using specific polyclonal antibodies against human recombinant (hr) TNF alpha and hrIL-6 in conjunction with the protein A-gold complex, TNF alpha and IL-6 were shown in the mesangial cells, being particularly associated with the membranes of the rough endoplasmic reticulum. In addition, IL-6 also was present in glomerular immune deposits and occasionally in glomerular epithelial cells. In normal renal tissue the TNF alpha and IL-6 immunoreactivities were undetectable. The specific presence of TNF alpha and IL-6 in pathological specimens was shown by several control experiments. Thus, our results offered morphological support that TNF alpha and IL-6 might play a role in human lupus nephritis. The data showed their synthesis by the mesangial cells and their possible participation in the progression to chronicity of the renal injury on secretion.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7750940     DOI: 10.1016/0046-8177(95)90253-8

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  44 in total

Review 1.  Tumour necrosis factor and other cytokines in murine lupus.

Authors:  A N Theofilopoulos; B R Lawson
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  IL-6 Trans-Signaling Drives Murine Crescentic GN.

Authors:  Gerald S Braun; Yoshikuni Nagayama; Yuichi Maruta; Felix Heymann; Claudia R van Roeyen; Barbara M Klinkhammer; Peter Boor; Luigi Villa; David J Salant; Ute Raffetseder; Stefan Rose-John; Tammo Ostendorf; Jürgen Floege
Journal:  J Am Soc Nephrol       Date:  2015-06-03       Impact factor: 10.121

3.  In situ glomerular expression of activated NF-kappaB in human lupus nephritis and other non-proliferative proteinuric glomerulopathy.

Authors:  Ling Zheng; Raja Sinniah; Stephen I-Hong Hsu
Journal:  Virchows Arch       Date:  2005-10-05       Impact factor: 4.064

Review 4.  Cytokines as therapeutic targets in SLE.

Authors:  Lars Rönnblom; Keith B Elkon
Journal:  Nat Rev Rheumatol       Date:  2010-05-04       Impact factor: 20.543

5.  Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus.

Authors:  E Svenungsson; M Andersson; L Brundin; R van Vollenhoven; M Khademi; A Tarkowski; D Greitz; M Dahlström; I Lundberg; L Klareskog; T Olsson
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

Review 6.  Lupus nephritis: the evolving role of novel therapeutics.

Authors:  Brad H Rovin; Samir V Parikh
Journal:  Am J Kidney Dis       Date:  2014-01-07       Impact factor: 8.860

7.  Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus.

Authors:  S Zampieri; M Alaibac; L Iaccarino; R Rondinone; A Ghirardello; P Sarzi-Puttini; A Peserico; A Doria
Journal:  Ann Rheum Dis       Date:  2005-08-11       Impact factor: 19.103

Review 8.  Cytokines: Names and Numbers You Should Care About.

Authors:  Stephen R Holdsworth; Poh-Yi Gan
Journal:  Clin J Am Soc Nephrol       Date:  2015-05-04       Impact factor: 8.237

Review 9.  Anti-TNF-alpha therapies in systemic lupus erythematosus.

Authors:  Lang-Jing Zhu; Xiao Yang; Xue-Qing Yu
Journal:  J Biomed Biotechnol       Date:  2010-06-22

10.  The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus.

Authors:  Wenpu Zhao; Seth G Thacker; Jeffrey B Hodgin; Hongyu Zhang; Jeffrey H Wang; James L Park; Ann Randolph; Emily C Somers; Subramaniam Pennathur; Matthias Kretzler; Frank C Brosius; Mariana J Kaplan
Journal:  J Immunol       Date:  2009-07-20       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.